Ian T. Clark
Independent DirectorMr. Ian T. Clark has been an Independent Director of BioMarin Pharmaceutical Inc. from August 1, 2025 and serves as its Chairman of the Board since June 03, 2026. He served as Director at GoodRx, Inc. since July 2024 until August 2026. He had been a Director at GoodRx Holdings, Inc. since July 2024 until March 31, 2026. He served as the Chairman since September 2021 until January 11, 2026 and Independent Director of Kyverna Therapeutics, Inc. since September 2021. He serves as the Chairman of X-Vax Technology, Inc. He was an Executive Advisor of KKR & Co. Inc. He has been an Independent Director of Olema Pharmaceuticals, Incorporated since August 2020 and serves as its Independent Chairperson of the Board. He serves as a Director of Gyroscope Therapeutics Limited. He had been a Director of Asher Biotherapeutics, Inc. since February 2022 until September 2025 and served as its Chairman of the Board until September 2025. He serves as Senior Advisor of Blackstone Life Sciences Group at The Blackstone Group Inc. He had been an Independent External Director of Takeda Pharmaceutical Company Limited since January 8, 2019. He is a Non-Executive Director of Gyroscope Therapeutics Holdings Limited since March 2019. He served as an Operating Partner at Clarus Ventures, LLC since September 11, 2017. He has been Special Adviser to the Board at Immunocore Limited since May 12, 2017. He also serves as an Advisor to the Institute of Life Sciences at Southampton University. From September 2017 to September 2020, he was an Operating Partner at Blackstone Life Sciences. He serves as a Director of Olema Oncology. He served on the Board of Directors of Forty Seven Incorporated from May 2018 to April 2020. Prior to that, he was the Executive Vice President and Chief Marketing Officer of the Roche Group from April 2009 to December 2009. Prior to his time at the Roche Group, he held several senior management positions at Genentech Incorporated from January 2003 to March 2009. He spent many years in the biopharmaceutical industry in senior roles at Novartis International AG, Ivax Pharmaceuticals, Incorporated. He started his career at G.D. Searle, LLC, a subsidiary of Monsanto Corporation, holding positions in sales and marketing. He served as the Chief Executive Officer of Genentech Incorporated from January 2010 to December 2016 and as Head of Roche’s North American Commercial Operations. He served as Head of Global Product Strategy at Roche Holding AG since January 2010. He served as Head of North American Commercial Operations at Genentech, Inc. until December 31, 2016. He joined Genentech in 2003. He served as Senior Vice President of Commercial Operations at Genentech, Inc., from August 2005 to December 2005 and its Executive Vice President of Commercial Operations since December 2005 until 2010. He served as General Manager of BioOncology at Genentech since 2003 until 2010, its Senior Vice President since 2003 until 2010, its Executive Vice President of Global Marketing, its Head of Global Product Strategy since 2003 to 2010 and Chief Marketing Officer since April 2009 until 2010. He served as General Manager of Novartis Canada. He began his career at Searle, where he held management positions in both sales and marketing. He served as President of Novartis Canada from 2001 to 2003. During his tenure at Genentech, he led and executed the launch of over 14 new molecular entities, including Avastin and Tecentriq. He served as Chief Operating Officer for Novartis from 1999 to 2001. Prior to joining Novartis in 1999, he served in positions of increasing strategic importance in sales, marketing and business development at Ivax Pharma and Sanofi- Synthelabo. He also served as Chair of the External Advisory Board to Southampton University Institute for Life Sciences. He served as Vice President of sales and marketing for Sanofi (Aventis) and for Ivax in the United Kingdom, France and Eastern Europe. He serves as a Member of Executive Council at TechNet. He has been a Director of Guardant Health Inc. since January 2017 and serves as Lead Independent Director. He has extensive leadership and biotechnology sector experience. He has been a Director At Large of Biotechnology Innovation Organization since 2009. He served as Director at Shire Pharmaceuticals, Incorporated from February 2017 to January 2019. He has been a Director of InterMune, Inc. since September 29, 2014. He had been an Independent Director of Agios Pharmaceuticals, Incorporated since December 2016 until June 21, 2022. He served as a Non-Executive Director of Shire plc since January 3, 2017 until January 8, 2019. He has been an Independent Director of AVROBIO Inc. since January 2018. He served as an Independent Director of TerraVia Holdings, Inc. since April 2011. He had been an Independent Director of Corvus Pharmaceuticals, Inc. since January 03, 2017 until July 22, 2026. He serves on the Board of Biotechnology Industry Organization and Gladstone Foundation. He served as a Director of Kite Pharma, Inc. since January 5, 2017 until October 2, 2017. He is also on the BioFulcrum Board of the Gladstone Institutes. He served as a Member of the economic advisory council of the 12th District of the Federal Reserve. He served as a Director of Genentech, Inc. until December 31, 2016. He served as a Director of Dendreon Pharmaceuticals LLC from October 12, 2009 to September 2010. He served as Non-Executive Director of Vernalis Therapeutics from January 1, 2007 to December 31, 2009. He worked in the Bio-Pharma industry in positions of increasing seniority in Canada, the UK, France and Eastern Europe. He was selected as the San Francisco Business Times 2012 Most Admired Chief Executive Officer in the Public Companies category. He received a Bachelor of Science in biological sciences and an honorary Doctor of Science from Southampton University in the United Kingdom.
Positions
- Company NameKyverna Therapeutics, Inc.Stock CodeKYTXPositionIndependent Director
- Company NameBioMarin Pharmaceutical Inc.Stock CodeBMRNPositionIndependent Chair of the BoardColleagues
- AHAlexander HardyPresident, CEO & Director
- ITIan T. ClarkIndependent Chair of the Board
- BRBrian R. MuellerCFO & Executive VP of Finance
- CGC. Greg GuyerExecutive VP & CTO
- CHCristin HubbardExecutive VP & Chief Commercial Officer
- GFGregory FribergExecutive VP and Chief Research & Development Officer
- RJRobert J. HombachIndependent Director
- EMElizabeth McKee AndersonIndependent Director
- MJMark Joseph EnyedyIndependent Director
- Company NameOlema Oncology, Inc.Stock CodeOLMAPositionIndependent Chairperson of the BoardColleagues
- SPSean P. BohenPresident, CEO & Director
- ITIan T. ClarkIndependent Chairperson of the Board
- SMShawnte M. MitchellChief Legal Officer & Corporate Secretary
- JOJason O’ByrneCFO, Principal Financial Officer & Accounting Officer
- DCDavid C. MylesChief Scientific Officer
- COCourtney O'KonekVice President of Corporate Communications
- FPFrank P. McCormickChairman of Scientific Advisory Board
- CMCynthia Marie ButittaIndependent Director
- SGScott GarlandIndependent Director
- Company NameGuardant Health, Inc.Stock CodeGHPositionLead Independent DirectorColleagues
- HEHelmy EltoukhyCo-Founder, Co-CEO & Chairman
- ATAmirAli TalasazCo-Founder, Co-CEO & Director
- MBMichael BellChief Financial Officer
- DCDarya ChudovaChief Technology Officer
- JGJohn G. SaiaChief Legal Officer & Corporate Secretary
- ITIan T. ClarkLead Independent Director
- VGVijaya GaddeIndependent Director
- SESteve Edward KrognesIndependent Director
